Primaquine in vivax malaria: An update and review on management issues

  • Fernando D
  • Rodrigo C
  • Rajapakse S
  • 158

    Readers

    Mendeley users who have this article in their library.
  • 69

    Citations

    Citations of this article.

Abstract

Primaquine was officially licensed as an anti-malarial drug by the FDA in 1952. It has remained the only FDA licensed drug capable of clearing the intra-hepatic schizonts and hypnozoites of Plasmodium vivax. This update and review focuses on five major aspects of primaquine use in treatment of vivax malaria, namely: a) evidence of efficacy of primaquine for its current indications; b) potential hazards of its widespread use, c) critical analysis of reported resistance against primaquine containing regimens; d) evidence for combining primaquine with artemisinins in areas of chloroquine resistance; and e) the potential for replacement of primaquine with newer drugs.

Author-supplied keywords

  • Plasmodium vivax
  • Primaquine
  • Prophylaxis
  • Radical cure
  • Vivax Malaria

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free